Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lysine (K)-specific demethylase 1A | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.009 | 1 | 0.5 | |
Echinococcus multilocularis | lysine specific histone demethylase 1A | 0.0083 | 0.904 | 1 |
Toxoplasma gondii | histone lysine-specific demethylase LSD1/BHC110/KDMA1A | 0.0017 | 0 | 0.5 |
Plasmodium vivax | protoporphyrinogen oxidase, putative | 0.0017 | 0 | 0.5 |
Mycobacterium ulcerans | flavin-containing monoamine oxidase AofH | 0.0017 | 0 | 0.5 |
Mycobacterium ulcerans | oxidoreductase | 0.0017 | 0 | 0.5 |
Plasmodium vivax | lysine-specific histone demethylase 1, putative | 0.0017 | 0 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0017 | 0 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0017 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0024 | 0.096 | 0.096 |
Echinococcus granulosus | lysine specific histone demethylase 1A | 0.0083 | 0.904 | 1 |
Plasmodium falciparum | conserved Plasmodium protein, unknown function | 0.0017 | 0 | 0.5 |
Schistosoma mansoni | Lysine-specific histone demethylase 1 | 0.0083 | 0.904 | 1 |
Plasmodium falciparum | protoporphyrinogen oxidase | 0.0017 | 0 | 0.5 |
Toxoplasma gondii | histone lysine-specific demethylase | 0.0017 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.009 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0083 | 0.904 | 0.904 |
Mycobacterium ulcerans | dehydrogenase | 0.0017 | 0 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0017 | 0 | 0.5 |
Trypanosoma cruzi | UDP-galactopyranose mutase | 0.0017 | 0 | 0.5 |
Mycobacterium ulcerans | flavin-containing monoamine oxidase AofH | 0.0017 | 0 | 0.5 |
Mycobacterium ulcerans | protoporphyrinogen oxidase | 0.0017 | 0 | 0.5 |
Trypanosoma cruzi | UDP-galactopyranose mutase | 0.0017 | 0 | 0.5 |
Mycobacterium leprae | PROBABLE PROTOPORPHYRINOGEN OXIDASE HEMY (PROTOPORPHYRINOGEN-IX OXIDASE) (PROTOPORPHYRINOGENASE) (PPO) | 0.0017 | 0 | 0.5 |
Chlamydia trachomatis | protoporphyrinogen oxidase | 0.0017 | 0 | 0.5 |
Leishmania major | UDP-galactopyranose mutase | 0.0017 | 0 | 0.5 |
Mycobacterium ulcerans | monoamine oxidase | 0.0017 | 0 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0017 | 0 | 0.5 |
Plasmodium falciparum | lysine-specific histone demethylase 1, putative | 0.0017 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0083 | 0.904 | 0.904 |
Brugia malayi | amine oxidase, flavin-containing family protein | 0.0024 | 0.096 | 0.096 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | > 3000 nM | BindingDB_Patents: Inhibitor Screening Assay. The primary assay for compound inhibitory activity was the LSD1 Inhibitor Screening Assay Kit (Cayman Chemical Company, Ann Arbor, Mich.; Cayman Chemical Item Number 700120). Briefly, test compounds were diluted to 20.times. the desired test concentration in 100% DMSO and 2.5 .mu.L of the diluted drug sample was added to a black 384-well plate. The LSD1 enzyme stock was diluted 17-fold with assay buffer and 40 .mu.M of the diluted LSD1 enzyme was added to the appropriate wells. The reaction mixture comprised horseradish peroxidase, dimethyl K4 peptide (corresponding to the first 21 amino acids of the N-terminal tail of histone H3), and 10-acetyl-3,7-dihydroxyphenoxazine was then added to wells. Generation of resorufin (generated by reacting with H.sub.2O.sub.2 produced in the reaction) was analyzed on an Envision microplate reader with an excitation wavelength of 530 nm and an emission wavelength of 595 nm. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.